Complete Conference Management 30th Annual Heart Failure 2026
20.00 $
Description
Videos+SubtitlesÂ
NO PDFs in this course
+ Target Audience: cardiologists, internists, primary care physicians
+ Information:
1. Overview
The Complete Conference Management 30th Annual Heart Failure 2026 program provides a highly specialized, comprehensive review of advanced heart failure management. The curriculum covers the latest innovations in pharmacotherapy, device therapy, genetic testing, and complex clinical scenarios—such as cardiogenic shock, myocarditis, and peripartum cardiomyopathy—equipping cardiovascular specialists to optimize patient outcomes across diverse etiologies.
Course Date: March 13 & 14, 2026
The 30th Annual Heart Failure 2026: An Update on Therapy continues the tradition of providing a comprehensive update on the prevention, diagnosis, and management of heart failure. The program includes lectures presented by experts combined with an opportunity for interactive discussion with faculty. The extensive list of topics has been selected to provide high level and clinically relevant updates on the contemporary approach for the prevention and management of acute and chronic heart failure with the goal of improving clinicians’ knowledge and the care of patients with heart failure of various etiologies.
Once again in 2026, the symposium will be a hybrid event – attend in-person at the Millennium Biltmore Hotel or online!
2. Learning Objectives
At the conclusion of this activity, participants should be able to:
- Provide comprehensive updates on the management of cardiovascular conditions, including new guidelines for hypertension, therapeutic options for hyperlipidemia, and contemporary approaches to heart failure with reduced and preserved ejection fraction.
- Review advanced treatment strategies for complex cardiovascular scenarios, including acute decompensated heart failure, heart failure with kidney disease, atrial fibrillation in heart failure patients, and catheter-based interventions for valvular heart disease.
- Discuss specialized management approaches for specific cardiovascular conditions, including heart failure due to hypertrophic cardiomyopathy and amyloidosis, obesity in heart failure patients, and pulmonary arterial hypertension.
3. Target Audience
Best for cardiologists, advanced heart failure specialists, and intensivists who want updates on GDMT, cardiogenic shock, and cardiomyopathy management.
The program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.
4. Topics
| # | Session Title | Presenter(s) | Duration |
|---|---|---|---|
| 1 | Heart Failure: Artificial Intelligence and Remote Monitoring | Nir Uriel | 21:42 |
| 2 | Heart Failure: Autonomic Modulation Today and Future Directions | Marvin Konstam | 20:59 |
| 3 | LVAD vs Heart Transplant: Navigating Treatment Selection in Advanced Heart Failure | Nir Uriel | 18:25 |
| 4 | Transthyretin Amyloidosis: Individualizing Drug Therapy Selection for Clinical Practice | Mazen Hanna | 18:07 |
| 5 | Genetic Testing in Cardiovascular Disorders | Joshua Hare | 16:38 |
| 6 | Gene Therapy for Patients with Cardiomyopathy | Barry Greenberg | 22:31 |
| 7 | Cell and Gene Therapy for Cardiovascular Disorders | Joshua Hare | 20:28 |
| 8 | Methamphetamine-Associated Cardiomyopathy: Early Recognition, Cessation, and Long-Term Management | Uri Elkayam | 13:36 |
| 9 | HIV With Severe LV Dysfunction Presenting as Cardiogenic Shock | Anilkumar Mehra, Uri Elkayam, Barry Greenberg, Leslie T. Cooper | 28:14 |
| 10 | Atrial Fibrillation and Heart Failure: Rhythm Control, GDMT, and Risk Factor Management | Anil K. Bhandari | 25:06 |
| 11 | Heart Failure Management: 30 Years of Innovation and Evolving Standards | Clyde Yancy | 34:12 |
| 12 | Peripartum Cardiomyopathy Management With Bromocriptine: Pathophysiologic Rationale and Available Evidence | Uri Elkayam | 13:43 |
| 13 | Myocarditis: Updates From the ESC 2025 Guidelines | Leslie T. Cooper | 21:27 |
| 14 | Pulmonary Hypertension: New Therapies and Their Clinical Use | Thomas Heywood | 21:15 |
| 15 | Heart Failure: Innovations in Device Therapy | William Abraham | 20:52 |
| 16 | Hypertrophic Cardiomyopathy: Clinical Experience with Myosin Inhibitors in Obstructive and Nonobstructive Disease | Jessica Wang | 19:23 |
| 17 | Obesity in Patients With Heart Failure: Contemporary Management Strategies | Norman Lepor | 24:18 |
| 18 | GDMT for Chronic HFrEF: How to Maximize the Benefits? | Gregg Fonarow | 23:15 |
| 19 | Biomarkers and Omics in Heart Failure: Aids to Diagnosis and Therapy Monitoring | Kirkwood F. Adams | 21:43 |
| 20 | Treating Congestion in Acute Decompensated Heart Failure: Current Management and Future Directions | William Abraham | 20:38 |
| 21 | Cardio-Oncology: Recognizing and Managing Immune Checkpoint Inhibitor Myocarditis | Eric Yang | 21:10 |
| 22 | Diuretic Therapy: How Has Management Evolved Over 240 Years? | Marvin Konstam | 13:18 |
| 23 | Hospitalized Patients With Decompensated Heart Failure: Optimizing Inpatient Diuresis and Decongestion | Uri Elkayam | 14:31 |
| 24 | Hyperkalemia Management to Optimize RAASi and Maintain GDMT in Cardiorenal Disease | Ileana Pina | 23:33 |
| 25 | Heart Failure Management With Digitoxin and Digoxin: What Do DIG and DIGIT-HF Tell Us? | Tien Ng | 18:43 |
| 26 | Heart Failure and CKD: Integrating Finerenone Into Clinical Management | Akshay S. Desai | 18:30 |
| 27 | HFrEF: When and How to Use Vericiguat in Patients With Worsening Heart Failure | Barry Greenberg | 16:30 |
| 28 | HFpEF: Optimizing Guideline-Directed Medical Therapy Across the EF Spectrum | Akshay S. Desai | 19:14 |
| 29 | Cardiogenic Shock: Hemodynamic Classification and Management Strategies | Rola Khedraki | 23:03 |
| 30 | Ischemic Cardiomyopathy: Does Percutaneous Coronary Intervention Improve Outcomes? | Christina Economides | 22:35 |
Related products
